Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 19, 2016

View Archived Issues

Biallelic mutations in REV7 gene are associated with Fanconi anemia

Galecto Biotech patents galectin 3 ligands

Novel AR antagonists show promising activity in castration resistant prostate cancer

Akers Biosciences presents results for OxiCheck disposable breath test

Auris Medical's phase III trial of Keylizen does not meet its two coprimary efficacy endpoints

Xenetic Biosciences starts collaboration with Excivion to develop Zika vaccine

Hybrid CB1/iNOS antagonist ameliorates liver fibrosis in preclinical models

Insys Therapeutics enrolls first patient in phase II trial of canabidiol

Ambrx's IND for ARX-788 becomes active

Aclaris Therapeutics reports data from WART-201 phase II trial

NIH grants support work at Feinstein Institute on bioelectronic medicine and sepsis

Mayne Pharma acquires dermatology-related assets from GlaxoSmithKline

NIAID funding supports testing of Kineta's broad-spectrum antivirals in preclinical Zika models

Intellia presents preclinical data on in vivo gene editing with LNPs to deliver CRISPR/Cas9

Kancera describes ROR1 inhibitors

Bayer Healthcare develops sGC activators

Experimental inhibition of S100P gene reverses trastuzumab resistance in breast cancer

Kadimastem signs agreement with unnamed medical device company for diabetes-related device

Physiomics signs share purchase agreement with BioMoti

Chinese clinical trial authorization for TaiGen's furaprevir

Michael James Enterprises begins research on new dronabinol-based formulation for anorexia nervosa

Juniper Pharmaceuticals completes phase IIb trial of COL-1077

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...